Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Suzetrigine (Journavx) is the first non-opioid painkiller to be approved in the US in 20 years. It could help over 80 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback